Myriad Genetics Inc MYGN
Analyst Ratings
- Consensus
- Hold — 1 Buy · 4 Hold · 1 Sell (6 analysts)
- Avg. Price Target
- $4.02 (-40.4% downside)
Key Stats
- Today's Range
- $6.46 – $6.77
- 50-Day Range
- $2.92 – $6.77
- 52-Week Range
- $2.74 – $8.59
- Volume
- 698K shs
- Average Volume
- 2.74 million shs
- Market Cap
- $634.16 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 13.76%
- Days to Cover
- 27.81
About Myriad Genetics Inc
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Related Stocks
Compare head-to-head: MYGN vs IDXX·MYGN vs LNTH·MYGN vs CLDX·MYGN vs NTLA
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.